288 related articles for article (PubMed ID: 34966712)
61. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
62. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.
Gong J; Wan Q; Shang J; Qian X; Su D; Sun Z; Liu G
Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
[TBL] [Abstract][Full Text] [Related]
63. Cost-effectiveness analysis of case management for optimized antithrombotic treatment in German general practices compared to usual care - results from the PICANT trial.
Ulrich LR; Petersen JJ; Mergenthal K; Berghold A; Pregartner G; Holle R; Siebenhofer A
Health Econ Rev; 2019 Feb; 9(1):4. PubMed ID: 30729350
[TBL] [Abstract][Full Text] [Related]
64. [Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China].
Lin Y; Zhang SX; Yang PC; Cai YL; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):852-859. PubMed ID: 28738455
[No Abstract] [Full Text] [Related]
65. Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China.
Huang XM; Yang BF; Zheng WL; Liu Q; Xiao F; Ouyang PW; Li MJ; Li XY; Meng J; Zhang TT; Cui YH; Pan HW
BMC Health Serv Res; 2022 Feb; 22(1):260. PubMed ID: 35216586
[TBL] [Abstract][Full Text] [Related]
66. Potential cost-effectiveness of wearable cardioverter-defibrillator for patients with implantable cardioverter-defibrillator explant in a high-income city of China.
Jiang X; Ming WK; You JHS
J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2387-2396. PubMed ID: 31502350
[TBL] [Abstract][Full Text] [Related]
67. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
Zhan M; Zheng H; Xu T; Yang Y; Li Q
Lung Cancer; 2017 Aug; 110():1-6. PubMed ID: 28676211
[TBL] [Abstract][Full Text] [Related]
68. Cost-benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet.
Rognoni C; Armeni P; Tarricone R; Donin G
Clin Ther; 2020 Jan; 42(1):60-75.e7. PubMed ID: 31959413
[TBL] [Abstract][Full Text] [Related]
69. Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.
Alrawashdh N; McBride A; Slack M; Persky D; Andritsos L; Abraham I
J Manag Care Spec Pharm; 2022 Apr; 28(4):390-400. PubMed ID: 35332792
[No Abstract] [Full Text] [Related]
70. Cost-utility analysis of rhegmatogenous retinal detachment surgery in Shanghai, China.
Ma Y; Ying X; Zou H; Xu X; Liu H; Bai L; Xu X; Zhang X
Ophthalmic Epidemiol; 2015 Feb; 22(1):13-9. PubMed ID: 24527711
[TBL] [Abstract][Full Text] [Related]
71. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
[TBL] [Abstract][Full Text] [Related]
72. Economic Decision Model for First-Time Traumatic Patellar Dislocations in Adolescents.
Nwachukwu BU; So C; Schairer WW; Shubin Stein BE; Strickland SM; Green DW; Dodwell ER
Am J Sports Med; 2017 Aug; 45(10):2267-2275. PubMed ID: 28463547
[TBL] [Abstract][Full Text] [Related]
73. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
74. Digital Therapeutic Care Apps With Decision-Support Interventions for People With Low Back Pain in Germany: Cost-Effectiveness Analysis.
Lewkowicz D; Wohlbrandt AM; Bottinger E
JMIR Mhealth Uhealth; 2022 Feb; 10(2):e35042. PubMed ID: 35129454
[TBL] [Abstract][Full Text] [Related]
75. Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study.
Maru S; Byrnes JM; Carrington MJ; Stewart S; Scuffham PA
J Med Econ; 2017 Apr; 20(4):318-327. PubMed ID: 27841726
[TBL] [Abstract][Full Text] [Related]
76. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
Alkhatib N; Sweitzer NK; Lee CS; Erstad B; Slack M; Gharaibeh M; Karnes J; Klimecki W; Ramos K; Abraham I
Am J Cardiovasc Drugs; 2021 Mar; 21(2):205-217. PubMed ID: 32710439
[TBL] [Abstract][Full Text] [Related]
77. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
Xie X; Vondeling H
Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
[TBL] [Abstract][Full Text] [Related]
78. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Wu B; Shen J; Cheng H
BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
[TBL] [Abstract][Full Text] [Related]
80. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
